Discover your next big idea at PACK EXPO Las Vegas this September
Experience a breakthrough in packaging & processing and transform your business with solutions from 2,300 suppliers spanning all industries.

Schott Inaugurates Plant for Prefillable Polymer Syringes

The new manufacturing facility in Müllheim, Germany, includes a R&D center to drive rapid prototyping of new polymer syringe solutions, as well as a logistics and an integrated administrative area.

Schott Muellheim Factory

This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.

The international technology group Schott is celebrating the inauguration of its new Müllheim, Germany, manufacturing facility for prefillable syringes made of high-end polymer. “Today’s opening marks a big step in our strategic business expansion,” says Andreas Reisse, executive vice president of Schott’s pharma business unit. “The new facility in Müllheim aims to play an important role in supplying the global pharma industry with advanced drug delivery solutions made of polymer.”

The investment in the three-digit million Euro range includes a R&D center to further drive rapid prototyping of new polymer syringe solutions, as well as a logistics and an integrated administrative area. The facility will manufacture prefillable syringes made of advanced pharmaceutical-grade polymer used for a range of drugs, including mRNA-based formulations.

Schott’s prefillable polymer syringes are designed to safely store and administer highly viscous drugs, emergency, and intensive care medication, as well as cancer treatments. Most recently, new drug categories have entered the market, such as mRNA-based drugs, which can also be safely stored in prefillable polymer syringes. “We are ready to take the next step with major pharmaceutical companies developing next generation medications. Our validated polymer syringe systems meet the demanding requirements of new drug categories, including ultra-low temperature storage applications needed for mRNA-based applications,” says Mario Haas, vice president for the polymer solutions division of Schott’s pharma business unit.

The drug delivery solutions made of high-end polymer, more precisely cyclic olefin copolymer (COC), are break resistant, feature advanced barrier properties, and are biologically inert. The syringes known under the brand Schott Toppac® are manufactured in a state-of-the-art production environment: All manufacturing steps, from injection molding and quality control to sterile packaging, are automated and digitally connected in a cleanroom setting. Furthermore, the inspection technology makes use of machine learning and artificial intelligence principles, collecting data throughout the manufacturing to optimize process parameters.



Fill out the form below to request more information about Schott Inaugurates Plant for Prefillable Polymer Syringes
Smart Filling Equipment Selection Guide
Discover the six critical factors that determine filling equipment success and avoid costly selection mistakes that drain profits.
Read More
Smart Filling Equipment Selection Guide
Conveying Innovations Report
Editors report on distinguishing characteristics that define each new product and collected video demonstrating the equipment or materials as displayed at the show. This topical report, winnowed from nearly 300 PACK EXPO collective booth visits, represents a categorized, organized account of individual items that were selected based on whether they were deemed to be both new, and truly innovative, based on decades of combined editorial experience in experiencing and evaluating PACK EXPO products.
Take me there
Conveying Innovations Report